← golden set
AMGN
AMGEN INCHealthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $36.8B | RevenueFromContractWithCustomerExcludingAssessedTax | Total revenues |
| Operating income | $9.1B | OperatingIncomeLoss | Operating income |
| Net income attributable to the company | $7.7B | NetIncomeLoss | Net income |
| Diluted EPS | $14.23 | EarningsPerShareDiluted | Diluted |
| Cash and cash equivalents | $9.1B | CashAndCashEquivalentsAtCarryingValue | Cash and cash equivalents |
| Total assets | $90.6B | Assets | Total assets · Total liabilities and stockholders’ equity |
| Total liabilities | - | not reported | not in this filing's XBRL |
| Total shareholders' equity attributable to the company | $8.7B | StockholdersEquity | Total stockholders’ equity |
| Net cash from operating activities | $10.0B | NetCashProvidedByUsedInOperatingActivities | Net cash provided by operating activities |
| Net cash from investing activities | -$1.9B | NetCashProvidedByUsedInInvestingActivities | Net cash used in investing activities |
| Net cash from financing activities | -$10.9B | NetCashProvidedByUsedInFinancingActivities | Net cash (used in) provided by financing activities |
Income statement
table #86 · score 49.8 vs 32.5 runner-up · in millions| 2025 | 2024 | 2023 | |
| Revenues: | |||
| Product sales | 35,148 | 32,026 | 26,910 |
| Other revenues | 1,603 | 1,398 | 1,280 |
| Total revenues | 36,751 | 33,424 | 28,190 |
| Operating expenses: | |||
| Cost of sales | 12,037 | 12,858 | 8,451 |
| Research and development | 7,272 | 5,964 | 4,784 |
| Selling, general and administrative | 7,050 | 7,096 | 6,179 |
| Other | 1,312 | 248 | 879 |
| Total operating expenses | 27,671 | 26,166 | 20,293 |
| Operating income | 9,080 | 7,258 | 7,897 |
| Other income (expense): | |||
| Interest expense, net | (2,755) | (3,155) | (2,875) |
| Other income, net | 2,651 | 506 | 2,833 |
| Income before income taxes | 8,976 | 4,609 | 7,855 |
| Provision for income taxes | 1,265 | 519 | 1,138 |
| Net income | 7,711 | 4,090 | 6,717 |
| Earnings per share: | |||
| Basic | 14.33 | 7.62 | 12.56 |
| Diluted | 14.23 | 7.56 | 12.49 |
| Weighted-average shares used in the calculation of earnings per share: | |||
| Basic | 538 | 537 | 535 |
| Diluted | 542 | 541 | 538 |
Balance sheet
table #88 · score 51 vs 10 runner-up · in millions| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 9,129 | 11,973 |
| Trade receivables, net | 9,570 | 6,782 |
| Inventories | 6,225 | 6,998 |
| Other current assets | 4,133 | 3,277 |
| Total current assets | 29,057 | 29,030 |
| Property, plant and equipment, net | 7,913 | 6,543 |
| Intangible assets, net | 22,276 | 27,699 |
| Goodwill | 18,680 | 18,637 |
| Other noncurrent assets | 12,660 | 9,930 |
| Total assets | 90,586 | 91,839 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 2,367 | 1,908 |
| Accrued liabilities | 18,523 | 17,641 |
| Current portion of long-term debt | 4,599 | 3,550 |
| Total current liabilities | 25,489 | 23,099 |
| Long-term debt | 50,005 | 56,549 |
| Long-term deferred tax liabilities | 1,366 | 1,616 |
| Long-term tax liabilities | 2,690 | 2,349 |
| Other noncurrent liabilities | 2,378 | 2,349 |
| Contingencies and commitments (see Note 20) | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding-538.8 shares in 2025 and 536.9 shares in 2024 | 34,023 | 33,533 |
| Accumulated deficit | (25,107) | (27,590) |
| Accumulated other comprehensive loss | (258) | (66) |
| Total stockholders’ equity | 8,658 | 5,877 |
| Total liabilities and stockholders’ equity | 90,586 | 91,839 |
Cash flow statement
table #90 · score 53.5 vs 10 runner-up · in millions| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net income | 7,711 | 4,090 | 6,717 |
| Noncash adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, amortization and other | 5,167 | 5,592 | 4,071 |
| Impairment of intangible assets | 1,200 | 159 | 851 |
| Stock-based compensation expense | 494 | 530 | 431 |
| Deferred income taxes | (721) | (1,228) | (1,273) |
| (Gains) losses on equity securities | (2,064) | 159 | (1,565) |
| Other items, net | 149 | (177) | (277) |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Trade receivables, net | (2,676) | 441 | (1,015) |
| Inventories | 886 | 2,532 | 491 |
| Other assets | (1,267) | (652) | (564) |
| Accounts payable | 428 | 312 | (402) |
| Accrued income taxes, net | (2,068) | (1,011) | (1,031) |
| Long-term tax liabilities | 311 | (492) | 371 |
| Accrued liabilities | 499 | 92 | 953 |
| Accrued sales incentives and allowance | 2,065 | 1,194 | 935 |
| Other liabilities | (156) | (51) | (222) |
| Net cash provided by operating activities | 9,958 | 11,490 | 8,471 |
| Cash flows from investing activities: | |||
| Cash paid for acquisitions, net of cash acquired | (53) | - | (26,989) |
| Proceeds from sales of marketable securities | - | - | 1,123 |
| Proceeds from maturities of marketable securities | - | - | 550 |
| Purchases of property, plant and equipment | (1,858) | (1,096) | (1,112) |
| Other | (32) | 50 | 224 |
| Net cash used in investing activities | (1,943) | (1,046) | (26,204) |
| Cash flows from financing activities: | |||
| Net proceeds from issuance of debt | - | - | 27,777 |
| Extinguishment of debt | (683) | (659) | (647) |
| Repayment of debt | (5,000) | (3,600) | (1,454) |
| Repurchases of common stock | - | (200) | - |
| Dividends paid | (5,124) | (4,832) | (4,556) |
| Other | (52) | (124) | (72) |
| Net cash (used in) provided by financing activities | (10,859) | (9,415) | 21,048 |
| (Decrease) increase in cash and cash equivalents | (2,844) | 1,029 | 3,315 |
| Cash and cash equivalents at beginning of year | 11,973 | 10,944 | 7,629 |
| Cash and cash equivalents at end of year | 9,129 | 11,973 | 10,944 |